Thirona, a global company specializing in advanced analysis of thoracic CT images with artificial intelligence, is thrilled to announce the successful completion of its new investment. The Company has secured €7.5 Million ($8 Million) of financing through a €5 Million investment round from HERAN Partners and Borski Fund, and a €2.5 Million grant from the European Innovation Council (EIC).
Thirona is at the forefront of revolutionizing medical treatment and intervention pathways for lung diseases through cutting-edge artificial intelligence technologies, ultimately improving patient care and outcomes. The Company’s advanced capabilities in pre-operative and intra-operative imaging have the potential to significantly enhance the precision, accuracy, and efficiency of (robotic) bronchoscopic and surgical lung interventions, enabling easier-to-perform and less invasive procedures. Demonstrating consistently high performance across a wide range of diseases and pathologies, Thirona’s LungQ™ platform powers also a growing number of imaging-based exploratory research studies and clinical trials for the development of novel pharmaceutical drugs. Having surpassed a total number of 15 million images analyzed, the Company evolved into a technologically mature, globally recognized expert in advanced image analysis.
With this financing, Thirona plans to accelerate the adoption of its breakthrough innovations for precision medicine.
“We are very pleased with the confidence our investors have shown in our vision and capabilities,” said Eva van Rikxoort, Founder and CEO at Thirona. “This funding will enable us to continue pushing the boundaries of AI-powered imaging and help advance personalized treatment for lung patients around the world.”
Katleen Vandersmissen from HERAN Partners, one of the key investors of this round, expressed enthusiasm about the company’s potential impact, stating, “Thirona has demonstrated exceptional promise in the field of medical imaging. We are excited to support their mission to revolutionize healthcare through AI technology.”
According to Simone Brummelhuis from Borski Found, the latest investment will provide the company with the resources to expand its market presence. As Brummelhuis said, “Thirona has achieved major growth milestones, forged co-innovation partnerships with leading medical companies, and became a leader in the MedTech space for lung image analysis.”
Rita Priori, Chief Technology Officer at Thirona concludes, “The future of healthcare is undergoing a transformation, and we are at the forefront of this evolution, leading the way in our field. With the support of the investors, we are well geared to have our technology make a significant impact on patient care and the medical industry.”
About Thirona
Thirona is a global company providing high-precision advanced lung image analysis with artificial intelligence through expertise-based services for MedTech, pharmaceutical, and CRO companies. Thirona partners with research institutions and medical companies in their innovation programs aimed to enable breakthroughs in precision medicine for personalized treatment of pulmonary diseases. Since its inception in 2014, the Company has established a proven track record in translating technology into certified clinical end-products through co-innovation with leading MedTech companies.
Thirona’s state-of-the-art lung quantification platform LungQ™ consists of a comprehensive portfolio of robust high-performance AI-based algorithms trained on a wide range of disease-specific datasets, offering market-leading AI analytical capabilities. The unique, scalable AI platform delivers consistent and reproducible results, powering exploratory research studies as well as large multi-site clinical trials.
Founded by female scientist and entrepreneur Eva van Rikxoort, the company’s mission is to utilize the latest domain knowledge and artificial intelligence technology to create a positive impact by making personalized treatment in lung diseases accessible for everyone.
Originally announced September 11th, 2023
